Intensity Therapeutics ( INTS ), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results ...

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is one of the best stocks under $5 with highest upside potential. On October 28, ...

Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, announced the signing of a License Agreement with Japan-based RIN Institute Inc., granting Mycenax rights to apply RIN's prop ...

In recognition of Pancreatic Cancer Awareness Month, join us to explore how cutting-edge technologies are transforming our ...

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under ...

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

Glioblastoma is an aggressive brain cancer that almost always recurs after surgery and radiochemotherapy. Now, researchers ...

The poster will be available on November 7, 2025 under the “Our Approach—Presentations & Publications” section of the Xilio Therapeutics website at www.xiliotx.com.

Discover why Janux Therapeutics, Inc.'s promising immunotherapy data and strong cash position draw attention—plus key risks.

Scientists have developed a way to engineer immune cells that specifically target tumors. The application of engineering ...

Renal Cell Carcinoma (RCC): FDA approved oral Everolimus for advanced RCC after failure of sunitinib and/or sorafenib. Approval was based on RECORD-1 randomized phase III (everolimus 10 mg PO daily vs ...